Literature DB >> 12097200

Rarity of encephalopathy associated with autoimmune thyroiditis: a case series from Mayo Clinic from 1950 to 1996.

Anna M Sawka1, Vahab Fatourechi, Bradley F Boeve, Bahram Mokri.   

Abstract

Corticosteroid-responsive encephalopathy associated with autoimmune thyroiditis (also called Hashimoto's encephalopathy) is a rare, life-threatening, treatable, and possibly autoimmune condition. We identified nine patients (with the diagnosis made after 1979) who had relapsing encephalopathy compatible with previous reports of Hashimoto's encephalopathy and no other identifiable cause of encephalopathy at Mayo Clinic Rochester. Of these nine patients, three were clinically hypothyroid, four were subclinically hypothyroid, and two were euthyroid. Thyroid antibodies were positive in eight of eight patients in whom these measurements were made. Electroencephalographic abnormalities were identified in eight of the nine patients (89%). Magnetic resonance imaging (MRI) abnormalities considered etiologically related to encephalopathy were present in three patients (33%). An increased protein concentration was noted on cerebrospinal fluid examination in seven patients (78%). Of the six patients who received high-dose glucocorticoid therapy, 5 (83%) had improvement of neurologic symptoms. In conclusion, encephalopathy associated with autoimmune thyroiditis is rare but important to recognize because it may be responsive to high-dose glucocorticoid therapy. We believe that this condition is not caused by thyroid dysfunction or antithyroid antibodies but represents an association of an uncommon autoimmune encephalopathy with a common autoimmune thyroid disease. The term Hashimoto's encephalopathy is a misnomer and should not be used.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097200     DOI: 10.1089/105072502760043477

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  16 in total

1.  Hashimoto's encephalopathy presenting with psychosis and generalized absence status.

Authors:  Andrew McKeon; B McNamara; B Sweeney
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  Clinical and diagnostic aspects of encephalopathy associated with autoimmune thyroid disease (or Hashimoto's encephalopathy).

Authors:  Gianluca Tamagno; Giovanni Federspil; Giovanni Murialdo
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

4.  14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy.

Authors:  T Vander; C Hallevy; I Alsaed; S Valdman; G Ifergane; I Wirguin
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

5.  Focal neurological presentation in Hashimoto's encephalopathy mimicking a vascular occlusion of the middle cerebral artery.

Authors:  Ahmad Alazzeh; Sarah Jaroudi; Matthew Gooch; Alan N Peiris
Journal:  BMJ Case Rep       Date:  2017-07-14

Review 6.  Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

Authors:  Ramon Mocellin; Mark Walterfang; Dennis Velakoulis
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Rapidly progressive young-onset dementia.

Authors:  Brendan J Kelley; Bradley F Boeve; Keith A Josephs
Journal:  Cogn Behav Neurol       Date:  2009-03       Impact factor: 1.600

Review 8.  Hashimoto's encephalopathy: a brief review.

Authors:  Howard S Kirshner
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

9.  Steroid-responsive encephalopathy: an under recognised aspect of Hashimoto's thyroiditis.

Authors:  Tanawan Riangwiwat; Jutarat Sangtian; Chutintorn Sriphrapradang
Journal:  BMJ Case Rep       Date:  2015-03-12

10.  Encephalopathy associated with autoimmune thyroid disease in patients with Graves' disease: clinical manifestations, follow-up, and outcomes.

Authors:  Gianluca Tamagno; Yahya Celik; Rafael Simó; Marcel Dihné; Kazumi Kimura; Giorgio Gelosa; Byung I Lee; Caroline Hommet; Giovanni Murialdo
Journal:  BMC Neurol       Date:  2010-04-28       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.